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Figure S1. Representative 1H NMR of top: redox-responsive hyperbranched polymer (HB-SS-
HH) and bottom: non-degradable hyperbranched HPMA (HB-HPMA-S).  
Figure S2. 1H NMR spectra of top) Star-SS-L, middle) Linear-SS and bottom) Micelle-SS. 
Figure S3. Critical micelle concentration (CMC) plots for the linear, micelle and star pHPMAs. 
Figure S4. Stability of non-degradable and redox-responsive pHPMAs in cell culture DMEM 
over 48 h incubation at 37 ºC 
Figure S5. Stability of pHPMAs to protein corona binding assayed by DLS at A) 0.2 wt% BSA 
and B) 1 wt% BSA. 
Figure S6. In vitro cell viability for all pHPMA materials in triple negative breast cancer cells. 
Figure S7. In vitro data depicting A) metabolic activity and B) LDH release of pHPMAs after 
24h incubation with RAW 264.7 macrophages 
Figure S8. Macrophage uptake data showing A) influence of size on uptake (4h), B) 
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Figure S9. Fluorescence microscopy confirming intracellular localization of pHPMAs during 
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Figure S24. 1H NMR spectra of CBMA 
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1-Amino-2-propanol (>99%), methacryloyl chloride (97%), 4,4′-azobis(4-cyanovaleric acid) 
(V-501, >97%), 1-Bromobenzene (99%), cysteamine (>98%), pentafluorophenol (>99%), N-
(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (98%), magnesium turnings 
(98%), 4-(dimethylamino)pyridine (98%), carbon disulphide (99%), iodine (99.99%), sodium 
thiosulfate (98%), methacrylic anhydride (94%), ethylenediamine (>99%), pyridine (99.8%), 
triethylamine (TEA, >98%), Bovine Serum Albumin (BSA, >98%) and Lactic Dehydrogenase 
(LDH) Toxicology Assay Kit (TOX7 kit) were purchased from Sigma-Aldrich (Poole, U.K.). 
Cyanine5 (Cy5) amine fluorescent dye was purchased from Lumiprobe. AlamarBlue™ Cell 
Viability Reagent, PrestoBlue® Cell Viability Reagent and Potassium hexacyanoferrate(III) 
(98%) were purchased from Thermo Fisher Scientific. All other chemicals and solvents were 
analytical or HPLC grade and purchased from Fisher Scientific. Methacryloyl chloride was 
distilled under Ar flow before use. All other chemicals were used as received unless otherwise 
stated. 
Characterization 
1H NMR, 13C NMR, 19F NMR spectra were recorded on a Bruker DPX 400 UltraShield™ 
Spectrometer (400 MHz) using deuterated solvents from Aldrich. Spectra were processed with 
MestReNova 9.0.1 software. All chemical shifts are reported in ppm (δ) relative to the chemical 
shifts of deuterated solvents. Multiplicities are described with the following abbreviations: s = 
singlet, br = broad, d = doublet, t = triplet, m = multiplet. Mass spectrometry was carried out 
using a Micromass LCT ToF with electrospray ionization and OpenLynx software. Samples 
were prepared in MeOH. Size exclusion chromatography-multi-angle static light scattering 
(SEC-MALS) was carried out using a Wyatt Dawn 8+ 1260 Infinity II series in a system 
equipped with a Polymer Labs aquagel-OH guard column (50 x 7.5 mm, 8 µm) followed by a 
PL aquagel-OH MIXED-H analytical column. The mobile phase was 0.1 M NaNO3 with a flow 
rate of 1 mL min−1. Number average molecular weight (Mn) and dispersity (Đ) were calculated 
using a Wyatt DAWN® HELEOS® II MALS, using a dn/dc of 0.158. The resulting 
chromatograms were analyzed using ASTRA® software, V.6.1.2.84 (Wyatt Tech Corp). 
Dynamic Light Scattering (DLS) measurements were conducted in triplicate using a Malvern 
Zetasizer Nano ZS at 25oC (scattering angle 173o, laser of 633 nm) or a Viscotek 802 DLS with 
a laser wavelength of 830 nm at 20 ⁰C. Polymer solutions were prepared as 1 mg/mL in PBS. 
Data was analyzed using OmniSIZE software. A minimum of 10 measurements were collected 
per sample. The Zeta Potential of nanoparticles was evaluated according to the electrophoretic 
mobility of the particles and calculated by the Helmholtz-Smoluchowsky equation. All 
measurements were performed in triplicate. Transmission electron microscopy (TEM) images 
were acquired using a JEOL 2000-FX TEM with a tungsten source operating at an accelerating 
voltage of 80 kV equipped with a Gatan Orius SC1000 camera. To prepare the samples for 
imaging, each polymer was dissolved in DI H2O at a concentration of either 0.1 or 0.2 mg/mL 
and then passed through a 0.22 μm PES filter onto carbon coated Formvar copper grid and 
allowed to dry. Fluorescence microscopy images were acquired on an inverted Nikon Eclipse 
TE 300 microscope on bright-field, DAPI and Cy5 filters. Images were merged using ImageJ 
software (1.50i). The in vivo data was obtained using an IVIS® Spectrum imaging system 




Synthesis of N-(2-hydroxypropyl)methacrylamide (HPMA) 
HPMA was synthesized as previously reported.26,46 Methacryloyl chloride (14.9 mL, 152.44 
mmol) in 40 mL acetonitrile was added dropwise over an hour to a solution of 1-amino-2-
propanol in 85 mL acetonitrile at 0 °C under vigorous stirring, and the reaction mixture was 
stirred for a further 30 min. The precipitated 2-hydroxypropylammonium chloride was 
removed by filtration and the solvent removed under reduced pressure. The product was 
purified by repeated crystallization from acetone (mp = 70 °C) and stored at 8 °C (20.5 g, 140 
mmol, 71 % yield). 1H NMR (400 MHz, CDCl3) δ 6.35 (s, 1H), 5.69 (s, 1H), 5.41 – 5.21 (m, 
1H), 4.03 – 3.76 (m, 1H), 3.77 – 3.53 (m, 1H), 3.43 (ddd, J = 13.9, 6.5, 3.1 Hz, 1H), 3.12 (ddd, 
J = 13.3, 7.6, 5.1 Hz, 1H), 1.92 (t, J = 1.2 Hz, 3H), 1.15 (d, J = 6.3 Hz, 3H). ESI-TOF-MS: 
m/z: [M + H] + calcd, 143.09; found, 144.15.  
 
(4-cyanopentanoic acid)-4-dithiobenzoate (CADB) 
CADB was synthesized based on a modified procedure of Moad and coworkers.93 1-
Bromobenzene (8.6 g, 55 mmol) was introduced over 15 min to a round bottomed flask 
containing anhydrous tetrahydrofuran (150 mL), magnesium turnings (1.4 g, 57 mmol), and a 
crystal of iodine. The reaction mixture was heated to 80 oC and allowed to reflux for 2 h, after 
which time no magnesium metal could be observed. The reaction mixture was then cooled to 
0 °C and carbon disulfide (8.3 g, 109 mmol) introduced dropwise, via a degassed syringe. A 
color change from clear to deep orange was observed, and the reaction mixture was allowed to 
reach room temperature. The crude magnesiumbromo dithiobenzoate was converted to 
dithiobenzoic acid with addition of conc. HCl (7.0 mL) and isolated by liquid extraction with 
diethyl ether (3 x 100 ml). The dithiobenzoic acid was then converted to sodium dithiobenzoate 
and extracted to the aqueous layer with a 2M NaOH solution (3 x 50 ml). The sodium 
dithiobenzoate was reduced to S,S’-bisdithiobenzoate with dropwise addition of potassium 
hexacyanoferrate (15.0 g in 150 mL of water) over 30 minutes, and the crude product dried 
overnight.  
S,S’-Bisdithiobenzoate (3.06 g, 10 mmol) and 4'4'-azobis(4-cyanovaleric acid) (4.2 g, 15 
mmol) was added to a round-bottomed flask containing ethyl acetate (100 mL) and refluxed 
for 18 h. The reaction mixture was concentrated on a rotary evaporator and purified by silica 
flash column chromatography using 70:30 hexane: ethyl acetate as mobile phase (5.2 g, 20 
mmol, 42 % yield). 1H NMR (400 MHz, DMSO-d6) δ 12.47 (s, 1H), 7.96 – 7.89 (m, 2H), 7.74 
– 7.66 (m, 1H), 7.52 (t, J = 7.8 Hz, 2H), 2.60 – 2.51 (m, 2H), 2.43 (d, J = 3.2 Hz, 2H), 1.92 (s, 
3H). ESI-TOF-MS: m/z: [M + H] + calcd, 263.01; found, 264.02. 
 
Ethylene Dimethacrylamide (EDMA) 
A solution of methacrylic anhydride (18 mL, 119.7 mmol) in DCM was added dropwise 
under vigorous stirring to an ice-cold suspension of ethylenediamine (2 mL, 29.9 mmol) and 
pyridine (4.8 mL, 59.83 mmol) in 10 mL DCM over 1 h. The reaction mixture was stirred 
overnight at room temperature. The solid was filtered off and the organic phase washed with 
deionized water (x3), acidic water (10 %) (x3), deionized water (x3), a solution of sodium 
bicarbonate in water (x3) and deionized water (x3). The solvent was removed under reduced 
pressure using a rotary evaporator and the resultant oil was kept at -20 °C until a precipitate 
formed. The product was further purified via precipitation from ethyl acetate (3.5 g, 18 mmol, 
60 % yield. 1H NMR (400 MHz, CDCl3) δ 6.62 (s, 2H), 5.74 (s, 2H), 5.35 (s, 2H), 3.55-3.47 
(m, 4H), 1.96 (s, 6H). ESI-TOF-MS: m/z: [M + H] + calcd, 196.12; found, 197.13. 
 
Synthesis of tert-butyl 2-methacryloylhydrazinecarboxylate (t-butoxycarbonyl (boc)-
protected hydrazide methacrylate (tBHM))  
Tert-butyl carbazate (5 g, 37.8 mmol) and pyridine (5.98 mL, 75.6 mmol) were added to 
DCM (5 mL) on ice. Methacrylic anhydride (8.41 mL, 56.7 mmol) was added dropwise slowly 
over half an hour. The solution was then warmed to room temperature and stirred for 24 hours.  
The reaction was washed with 10% HCl (2 x 50 mL), distilled water (2 x 50 mL) and 
NaHCO3 (2 x 50 mL). The organic phase was collected and dried with anhydrous MgSO4 and 
concentrated. The product was recrystallised three times from hexane:EtOAc (4:1 v/v) (2.45 g, 
12 mmol, 33 % yield). 1H NMR (400 MHz, DMSO-d6) δ 9.66 (2, 1H), 8.72 (s, 1H), 5.71 (s, 
1H), 5.42 (s, 1H), 1.86 (d, J = 1.2 Hz, 3H), 1.41 (s, 9H). ESI-TOF-MS: m/z: [M + H] + calcd, 
200.12; found, 200.97. 
Synthesis of N,N-Cystaminebismethacrylamide (CBMA) 
Cystamine dihydrochloride (9.0 g, 40 mmol) was dissolved in 80 mL of water. An aqueous 
solution of sodium hydroxide (16 mL, 10 M) was added into the above solution, and then the 
mixture was stirred at 0 ºC for 20 min. Methacryloyl chloride (8.36 g, 80 mmol, in 10 mL of 
dichloromethane) was added dropwise into the above mixture at 0 °C, while a white precipitate 
was formed. The reaction mixture was stirred for a further 1 h, and then the mixture was 
filtered, and the solid was collected and then washed with deionized water (x3). The product 
was obtained by crystallization from ethyl acetate (7.2 g, 25 mmol, 62.5% yield). 1H NMR 
(400 MHz, CDCl3) δ 6.54 (s, 1H), 5.77 (t, J = 1.1 Hz, 2H), 5.38 (q, J = 1.5 Hz, 2H), 3.67 (q, J 
= 6.1 Hz, 4H), 2.91 (t, J = 6.4 Hz, 4H), 2.02 – 1.97 (m, 6H). ESI-TOF-MS: m/z: [M + H] + 
calcd, 288.42; found, 289.52.  
 
Synthesis of disulfide-linked bis-CADB (CADB-SS-CADB) 
CADB RAFT agent (300 mg, 1.1 mmol), pentafluorophenol (217 mg, 1.2 mmol) and 4-
dimethylaminopyridine (26 mg, 0.2 mmol) were stirred in dichloromethane (3 mL) at 0 ºC for 
10 min. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 200 mg, 1.3 mmol) in 3 mL 
dichloromethane was added dropwise over 30 mins. The reaction was stirred at 0 ºC for a 
further 2 hours, and then at room temperature overnight.  
The crude product was washed with acidic water (20 mL), distilled water (20 mL) and brine 
(20 mL). The organic phase was dried with MgSO4 and the solvent removed by a rotary 
evaporator to yield a pink oil. The product was purified by column chromatography using 
chloroform as eluent, with the product eluting as the first fraction.   
Cystamine dihydrochloride (46 mg, 0.2 mmol) was dissolved in 5 mL DMF. TEA (41 mg, 
0.4 mmol) was slowly added, and the reaction stirred for 10 minutes. CPTPA-PFP (200 mg, 
0.45 mmol) was dissolved in 1 mL DMF and added dropwise to the cystamine solution and 
stirred at room temperature overnight. The product was purified by column chromatography 
(Hexane:Ethyl Acetate 70:30) with the product eluting as the first fraction (290 mg, 0.43 mmol, 
43% yield). 1H NMR (400 MHz, DMSO-d6) δ 8.26 (ddt, J = 18.1, 12.1, 5.5 Hz, 2H), 7.98 – 
7.87 (m, 4H), 7.72 – 7.60 (m, 2H), 7.60 – 7.46 (m, 4H), 3.37 (d, J = 3.3 Hz, 4H), 2.78 (t, J = 
6.7 Hz, 4H), 2.51 – 2.33 (m, 4H), 2.13 (dddd, J = 36.9, 14.3, 9.3, 4.5 Hz, 4H), 1.91 (d, J = 1.9 
Hz, 6H). ESI-TOF-MS: m/z: [M + H] + calcd, 674.10; found, 675.11.  
 
Synthesis of Poly[N-(2-hydroxypropyl)methacrylamide] (pHPMA) in varying architectures 
by RAFT Polymerization 
Non-degradable hyperbranched polymers 
RAFT polymerizations of hyperbranched HPMA were carried out following a known 
standard protocol.[64] Briefly, HPMA (188 mg, 1.3 mmol) was dissolved in milliQ water (360 
µL) along with CADB RAFT agent (18.4 mg, 0.066 mmol), EDMA (12.9 mg, 0.066 mmol) 
and V-501 (3.7 mg, 0.013 mmol) in a reaction flask and sealed with a rubber septum reinforced 
with a cable tie. The solution was bubbled with argon for 30 minutes and then stirred at 70 °C 
for 24 h. The reaction mixture was then precipitated with acetone and unreacted monomer and 
impurities removed by dialysis in pure water for 48 hours. The polymer was analyzed by 1H 
NMR and SEC and labelled as HB-HPMA-S. 1H NMR (400 MHz, DMSO) δ 7.33-7.04 (s, 1H), 
4.90-4.60 (s, 1H), 3.82-3.57 (s, 1H), 3.10-2.73 (s, 2H), 2.05-0.42 (broad, m, 8H, CH2 and CH3 
of polymer backbone and CHCH3). 
Chain extension of non-degradable hyperbranched polymer 
To produce a larger sized particle, HB-HPMA was chain extended with additional HPMA at 
a target DP of 150. HB-HPMA (50 mg, 0.0025 mmol), HPMA (54 mg, 0.38 mmol) and ACVA 
(0.07 mg, 0.25 µmol) were dissolved in milliQ water (375 µL) in a reaction flask and sealed 
with a rubber septum reinforced with a cable tie. The solution was bubbled with argon for 30 
minutes and then stirred at 70 °C for 6 h and purified as above. The resultant polymer was 
labelled as HB-HPMA-L.  
Redox-responsive hyperbranched polymer architectures  
A hyperbranched polymer with 20 mol% content of a hydrophobic drug loading monomer 
was synthesized as follows. HPMA (150 mg, 1.1 mmol) was dissolved in distilled water (600 
µL) along with CADB RAFT agent (37 mg, 0.13 mmol), tBHM (53 mg, 0.26 mmol), CMBA 
(38 mg, 0.13 mmol) and V-501 (7.3 mg, 0.026 mmol) in a reaction flask and sealed with a 
rubber septum reinforced with a cable tie. The solution was bubbled with argon for 30 minutes 
and then stirred at 70 °C for 24 hours. The reaction mixture was then precipitated with acetone 
and unreacted monomer and impurities removed by dialysis for 48 hours. The polymer was 
analyzed by 1H NMR and SEC and labelled HB-SS-HH. 1H NMR (400 MHz, DMSO) δ 7.33-
7.04 (s, 1H), 4.90-4.60 (s, 1H), 3.82-3.57 (s, 1H), 3.10-2.73 (s, 2H), 2.05-0.42 (broad, m, 8H, 
CH2 and CH3 of Polymer backbone and CHCH3). 
A hyperbranched polymer with a lower hydrophobic content of 5 mol% was synthesized as 
above with the modifications of HPMA (179 mg, 1.25 mmol) and tBHM (13 mg, 0.066 mmol) 
as the monomer ratios. The resultant polymer was labelled as HB-SS-LH.  
Redox-responsive star architecture 
Star architecture polymers were achieved through chain extension of a HB core polymer with 
two different target DPs (50 and 100) of HPMA to form two sizes of larger branched molecule. 
Briefly, HB-SS-HH (100 mg, 0.0167 mmol) was dissolved in distilled water (900 µL) along 
with HPMA (119 mg, 0.834 mmol, Star-SS-S) or (239 mg, 1.67 mmol, Star-SS-L) and V-501 
(0.47 mg, 0.0017 mmol) in a reaction flask and sealed with a rubber septum reinforced with a 
cable tie. The solution was bubbled with argon for 30 minutes and then stirred at 70 °C for 6 
hours. The resultant polymers were purified and characterized as above.  
Redox-responsive linear architecture 
A high molecular weight linear random copolymer was synthesized with a single disulfide 
bridge utilizing the bis-RAFT synthesized above. Briefly, HPMA (572 mg, 4 mmol), tBHM 
(43 mg, 0.4 mmol), CADB-SS-CADB RAFT agent (3.4 mg, 0.005 mmol) and V-501 (0.14 mg, 
0.5 µmol) were dissolved in milliQ water (4 mL) in a reaction flask and sealed with a rubber 
septum reinforced with a cable tie. The solution was bubbled with argon for 30 minutes and 
then stirred at 70 °C for 6 hours. The resultant polymers were purified and characterized as 
above.  
Redox-responsive micellar architecture 
A HPMA macro-RAFT agent was synthesized as follows. HPMA (258 mg, 1.8 mmol), 
CADB RAFT agent (3.4 mg, 0.012 mmol) and V-501 (0.34 mg, 0.0012 mmol) were dissolved 
in milliQ water (1.8 mL) in a reaction flask and sealed with a rubber septum reinforced with a 
cable tie. The solution was bubbled with argon for 30 minutes and then stirred at 70 °C for 4 
hours. The reaction mixture was then precipitated with acetone three times and the resultant 
polymer was dried under vacuum prior to the next step.  
Disulfide crosslinked micelles were synthesized through RAFT aqueous dispersion 
polymerization as follows. HPMA macro-CTA (200 mg, 0.01 mmol), tBHM (60 mg, 0.3 
mmol), CBMA (29 mg, 0.1 mmol) and V-501 (0.3 mg, 0.001 mmol) were dissolved in milliQ 
water (2.5 mL, 10% w/w solids) in a reaction flask and sealed with a rubber septum reinforced 
with a cable tie. The solution was bubbled with argon for 30 minutes and then stirred at 70 °C 
for 8 hours. The crosslinked micelles were isolated by precipitation in acetone, followed by 
dialysis for 48 hours.   
 
Labelling of pHPMA with Cy5  
All pHPMA architectures were labelled with Cy5-amine for imaging in vitro and in vivo 
through an amidation reaction onto the terminal RAFT agent carboxylic acid groups at a 1:0.5 
ratio of polymer:dye as follows. HB-SS-HH (20 mg, 5 µmol), pentafluorophenol (1 mg, 5 
µmol) and DMAP (0.1 mg, 1 µmol) were dissolved in DMSO/H2O (50% v/v) on ice and stirred 
for 30 minutes. EDC (1 mg, 6 µmol) in the same solvent was added dropwise to the reaction, 
and stirred over ice for a further 2 hours. The reaction was then warmed to room temperature 
and stirred overnight. The reaction mixture was dried under high vacuum, and redissolved in 
DMF without purification. Cy5 amine (1.5 mg, 2.5 µmol) was dissolved in DMF (1 mL) and 
TEA (0.2 mg, 2.5 µmol) was slowly added. The solution was stirred for 10 minutes, and then 
added dropwise to the pHPMA-PFP solution. Polymers were purified by precipitation in 
acetone, followed by dialysis in pure water for 48 hours until the dialysis water was clear and 
the SEC trace of the labelled polymer showed a single peak detected by UV at 650 nm.  
 
Boc-deprotection 
Two candidate polymer architectures were selected for drug delivery efficacy investigations, 
HB-SS-HH and Star-SS-L. A predetermined amount of polymer (150 mg) was dissolved in dry 
MeOH (2 mL). TFA (0.5 mL) was slowly added to the polymer mixture and let stirring for 1 




HB-SS-HH or Star-SS-L (30 mg) were dissolved in 1mL dry methanol in a glass vial 
equipped with a stirrer bar. DOX.HCl (1.2x excess) was added and the reaction stirred 
overnight at 35 °C. The reaction was purified by precipitation into cold acetone 3x following 
by dialysis in PBS for 24 hours. DOX attachment was characterised by 1H NMR and UV–Vis 
microscopy (ex = 480 nm). 
 
Critical Micelle Concentration studies 
In order to determine the critical micelle/aggregation concentrations of the pHPMA 
materials, a DLS method was utilized. From a stock solution of polymer (500 µg/mL) in PBS, 
a multipipettor was employed to dilute to predetermined concentrations (100, 50, 25, 15, 10, 5, 
2.5, 1, 0.5, 0.25 µg/mL). The count rate of each dilution was measured using DLS, and plotted 
as a function of the polymer concentration. A straight line was fitted to each linear segment 
and the CMC/CAC was determined as the point at which the two lines intersected.  
 
Stability studies 
To determine the stability of pHPMAs under physiologically relevant conditions, each 
polymer architecture was dispersed in DMEM cell culture media at 500 µg/mL and incubated 
at 37 °C for different times. Size measurements of the samples were taken at 0 h, 24 h and 48 
h of incubation. To determine the stability of the redox-responsive pHPMAs under reductive 
conditions, each polymer was dispersed in PBS 10 mM pH 7.4 enriched with GSH (10 mM) at 
500 µg/mL and incubated at 37 °C for different times. Size measurements of the samples were 
taken by dynamic light scattering on a Zetasizer after 1 h, 24 h and 48 h of incubation. 
 
Protein binding assay 
To determine protein corona association to the pHPMAs, binding studies were undertaken 
using bovine serum albumin (BSA) as the model protein. Each polymer architecture (1 mg/mL 
in PBS) was sized by DLS at a fixed attenuation (11), and then BSA was added at low (0.2 
wt%, equivalent to DMEM+10% FBS) or high (1 wt%) concentrations. The samples were 
incubated at 37 °C and size measurements of the samples were taken by dynamic light 
scattering on a Zetasizer after 1 h and 24 h. 
 
In vitro buffer release study 
Phosphate buffer solutions at pH 5.5 and 7.4 were used to simulate endosomal and 
physiological pH. A calibration curve of DOX. HCl was prepared by measuring seven 
concentrations in pH 7.4 phosphate buffer in a 96 well plate. The excitation and emission 
wavelengths were 480 nm and 580 nm respectively. The samples were measured in a Tecan 
plate reader at a depth of 19 mm with 10 flashes and an integration time of 20 μs. 
The following release study was performed in triplicate to account for statistical variation 
between subsets. 1.0 mg of polymer prodrug was dissolved in 500 µL pH 7.4 phosphate buffer. 
The dissolved polymer was added into a Slide-A-Lyzer™ MINI Dialysis Device (3.5K 
MWCO) and the receptor tube was filled with 15 mL of either pH 7.4 or 5.5 phosphate buffer. 
All samples were stirred at 37 °C for 72 h. Aliquots of the dialysis buffer (1 mL) were removed 
at various time points, replacing with fresh buffer. The samples were measured on the plate 
reader using the same settings as the standards. 
 
Cell culture 
RAW 264.7 murine macrophages were obtained from the American Type Culture Collection 
(ATCC; Manassas, Virginia) and used in a passage window of 10. MDA-MB-231 cells and 
MDA-MB-468 cells were obtained from the American Type Culture Collection (ATCC; 
Manassas, Virginia) and used in a passage window of 16. Cells were cultured in DMEM 
(Sigma-Aldrich) or RPMI (Sigma-Aldrich) supplemented with 10% (v/v) FBS (Sigma-
Aldrich) and 2 mM L-glutamine (Sigma-Aldrich), and at 37 °C with 5% CO2. 
 
Cytocompatibility evaluation in breast cancer cells 
The cytotoxicity of the pHPMA materials was assessed using an AlamarBlue™ Cell 
Viability assay. MDA-MB-231 and MDA-MB-468 cells were seeded into a 96 well-plate at a 
density of 4 x 103 cells per well, and were allowed to adhere in growth media overnight at 37 
°C and 5% CO2. Cell media were discarded and replaced with fresh media (100 μL) containing 
different concentrations of pHPMA (100, 250, 500, 750 and 1000 µg/mL) for 48 hours. Cell 
viability was then assessed by addition of 10 µL alamarBlue to each well, with incubation for 
a further 4 hours. Fluorescence readings were measured using a Tecan plate reader at an 
excitation/emission of 530-560⁄590 nm. Fluorescence readings of blank wells (no cells) were 
subtracted from all readings and then cell viability values were determined as a ratio to cells 
grown in the absence of test compounds.  
For DOX-conjugated pHPMAs, cytocompatibility assays were conducted as follows. The 
AlamarBlue™ Cell Viability assay was performed to assess the effects of free DOX and 
pHPMA-DOX in MDA-MB-231 cells. The cells were seeded at 1x104 cells per well in 96 well 
plates and cultured for 24 hours prior to assaying. Cell media was discarded and replaced with 
fresh media (100 µL) containing different concentrations of free DOX or pHPMA-DoX for 48 
hours.  Triton X-100 applied at 1% (v/v) was used as a cell death (positive) control and a vehicle 
control containing no nanoparticles used as a negative control. Cells were then washed twice 
with warm PBS and 100 µL 10% (v/v) AlamarBlue reagent diluted in medium was applied per 
well, with incubation for a further 4 hours. Fluorescence readings were measured using a Tecan 
plate reader at an excitation/emission of 530-560⁄590 nm. Relative metabolic activity was 
calculated by setting values from the negative control as 100% and positive control values as 
0% metabolic activity. 
 
Cytocompatibility evaluation in macrophages 
The lactate dehydrogenase (LDH) release assay and PrestoBlue™ Cell Viability assay were 
performed to assess nanoparticle cytotoxicity. RAW 264.7 cells were seeded at 1x104 cells per 
well in 96 well plates and cultured for 24 hours prior to assaying.  Nanoparticles were exposed 
to cells for 24 hours and applied in 100 µL phenol red free DMEM containing 10% (v/v) FBS 
and 2 mM L-glutamine.  Triton X-100 applied at 1% (v/v) applied in phenol red free medium 
was used as a cell death (positive) control and a vehicle control containing no nanoparticles 
used as a negative control. Following exposure, 50 µL of supernatant was collected per well 
for analysis of LDH content. Cells were then washed twice with warm PBS and 100 µL 10% 
(v/v) PrestoBlue reagent diluted in phenol red free medium applied per well for 60 minutes.  
The resulting fluorescence was measured at 560/600 nm (λex/λem). Relative metabolic activity 
was calculated by setting values from the negative control as 100% and positive control values 
as 0% metabolic activity. Assessment of LDH release was performed according to the 
manufacturer’s instructions and involved adding 100 µL LDH detection reagent to the collected 
supernatant samples and incubating at room temperature shielded from light for 25 minutes. 
Absorbance was then measured at 492 nm. Relative LDH release was calculated with the 
negative control absorbance at 492 nm taken as 0%, and the positive control, assumed to cause 
total cell lysis, as 100%. 
 
Macrophage uptake of nanoparticles assessed by spectrophotometry 
RAW 264.7 macrophages were plated in 12 well plates at a seeding density of 1.2x105 cells 
per well and cultured for 48 hours. Culture medium was then removed and 1 mL of 
nanoparticles applied in phenol red free medium. The time-dependence of uptake was assessed 
with a nanoparticle concentration of 50 µg/mL. Additionally, the concentration-dependence of 
uptake was investigated at a fixed time point of 2 hours. Following exposure, nanoparticle 
solutions were removed and cells washed three times with ice cold PBS. 500 µl of 1% (v/v) 
Triton X-100 solution applied in PBS was then added per well for 10 minutes at 37 °C.  To 
assess nanoparticle uptake, 100 µl of the resulting solution was collected per well and 
transferred to 96 well plates for the measurement of fluorescence at 640/680 nm (λex/λem). 
Quantification of nanoparticles uptake was achieved via calibration curves of known 
nanoparticle concentrations diluted in 1% (v/v) Triton X-100 in PBS solution. Values were 
normalized to viable cell number per well determined by the trypan blue exclusion test and cell 
counting on a haemocytometer.  
 
Macrophage uptake determined by fluorescence imaging  
RAW 264.7 macrophages were seeded at a density of 1x104 cells per well in 96 well plates 
and cultured for 48 hours. 100 µl of 50 µg/ml nanoparticle solutions were applied to cells for 
2 hours, followed by removal and three washes with ice cold PBS. 100 µl of Hoechst 33342 
(10 µg/ml) (ThermoFisher) diluted in PBS was then applied to cells for 10 minutes at 37°C 
with 5% CO2. Staining solution was removed and cells washed twice with PBS prior to the 
addition of 100 µl Fluorobrite DMEM (ThermoFisher) for imaging. Cells were imaged on an 
inverted Nikon Eclipse TE 300 microscope on bright-field, DAPI and Cy5 filters. Images were 
merged using ImageJ software (1.50i). 
 
Breast cancer cell uptake determined by fluorescence imaging  
MDA-MB-231 cells were seeded at a density of 1 x 105 cells per well in 12 well plates and 
cultured for 24 hours. 1 mL of culture medium containing free DOX, blank pHPMA or 
pHPMA-DOX was applied to cells for 1, 2 and 4 hours, followed by removal and three washes 
with ice cold PBS. Cells were then fixed in 4% paraformaldehyde (PFA) solution (0.5 mL) for 
10 minutes. The PFA was then removed and the cells washed twice with PBS, followed by 
staining of the nuclei with 0.5 mL of Hoechst 33342 (10 µg/ml) (ThermoFisher) diluted in PBS 
for 10 minutes at 37°C with 5% CO2. Staining solution was removed and cells were imaged on 
a Nikon Ti Eclipse inverted microscope with bright-field, DAPI, tdTomato and Cy5 filters. 
Images were merged using ImageJ software (1.50i).  
 
In vitro 3D cell viability assays 
Corning 7007 Ultra-low attachment (ULA) 96-well round bottom plates were used to culture 
the 3D spheroids. 80% confluent MDA-MB-231 monolayer cells were detached, collected and 
the cell number determined using the Biorad TC20 automated cell counter. A single-cell 
suspension was diluted in culture medium with the addition of Cultrex basement membrane 
extract (Cultrex-BME, 100 µg/mL) and cells were seeded at 1000 cells/well to generate 
spheroids (final volume of cell suspension in each well was 100 µL). The plates were then 
centrifuged at 300 RCF for 5 min and cultured for 3 days until visible spheroid formation.  
Free DOX, blank pHPMAs and pHPMA-DOX were prepared as solutions in media at 2x the 
concentration of 2D cell culture. 100 µL of sample was added to each well which already 
contained a single spheroid in 100 µL of medium (making the total volume 200 µL) and the 
plate incubated for 72 h (n = 4). Images were taken immediately prior to treatment and every 
day thereafter for 3 days for spheroid volume analysis. Images of the spheroids were taken with 
a Nikon Ti Eclipse inverted microscope.  
The volume of the spheroids was analyzed by measuring their cross-sectional area using the 
in-house open source macro for the FiJi distribution of ImageJ written by Ivanov.[111] The 
macro determines the area of each spheroid using an established threshold algorithm.[112] This 
automated process is robust with less than 5% variation found between the algorithm and 
manual measurement. The measured area (S) from the macro data of the 2D projection of the 
spheroid was then used to calculate the radius, �𝑟𝑟 =  �𝑆𝑆
𝜋𝜋
� and subsequently, the volume, 
�𝑉𝑉 =  4
3
𝜋𝜋𝑟𝑟3� of an equivalent sphere.[113] 
At 72 h post treatment of the spheroids, cell viability was measured using AlamarBlue™ 
Cell Viability assay. 100 µL of cell culture medium was removed from each well and replaced 
with 100 µL 10% (v/v) AlamarBlue reagent. The contents of the plate were mixed vigorously 
for 5 minutes to destroy the spheroid structure, and the plate was incubated for 4 hours. 




Values obtained from the experiments were analyzed using one-way ANOVA. In all cases, 
differences were considered significant when p*** < 0.001, p** < 0.01, and p* < 0.05. 
 
In vivo biodistribution of Cy5-labelled pHPMA 
In vivo biodistribution experiments were performed in order to assess distribution, organ 
accumulation and clearance of Cy5-labelled pHPMAs of different architectures. The 
experiments were conducted under the UK Home Office Licence number PPL P435A9CF8. 
LASA good practice guidelines, FELASA working group on pain and distress guidelines and 
ARRIVE reporting guidelines were also followed.  
8-9 week old female immunodeficient CD-1 NuNu mice were purchased from Charles River 
UK. Mice were maintained in Individually Ventilated Cages (Tecniplast UK) within a barriered 
unit, illuminated by fluorescent lights set to give a 12 hour light-dark cycle (on 07.00, off 
19.00), as recommended in the guidelines to the Home Office Animals (Scientific Procedures) 
Act 1986 (UK).  The room was air-conditioned by a system designed to maintain an air 
temperature range of 21 ± 2 ºC and a humidity of 55% ± 10%. Mice were housed in social 
groups, 3 per cage, during the study, with irradiated bedding and autoclaved nesting materials 
and environmental enrichment (Datesand UK). Sterile irradiated 5V5R rodent diet (IPS Ltd, 
UK) and autoclaved water was offered ad libitum. The condition of the animals was monitored 
throughout the study by an experienced animal technician. After a week’s acclimatization, the 
mice were randomly allocated by weight to the study groups of 6 mice per polymer type.  
After warming the mice in a thermostatically controlled heating box (Datesand UK), they 
were injected intravenously via the tail vein with 100 µl of a 500 µM solution of the selected 
polymer type in PBS. No adverse effects were observed following the injections or for the 
duration of the study. The concentration delivered was determined from a balance of non-
toxicity from in vitro analysis as well as sufficient fluorescent intensity for imaging in vivo. 
Prior to the study time points, the mice were anaesthetized with an injectable anesthetic 
combination (Anaestemine [ketamine]/Sedastart [medetomadine], Animalcare Ltd. UK) before 
being placed in the imaging system. Images were taken at 1h, 4h and 24h post-injection, and 
two mice in each group were culled by cervical dislocation, organs were dissected out and were 
imaged ex vivo at these time points, with the other mice being allowed to recover from the 
anesthetic with appropriate post procedural monitoring and therapy, including placing mice on 
a heat pad and providing fluid replacement via wet mash once awake. The organs excised and 
imaged were the kidneys, liver, spleen, pancreas, lung, heart, bladder, brain and lymph nodes 
(subiliac). A urine sample (25 µl) was also collected and imaged.  
All images were collected using the IVIS® Spectrum imaging system, PerkinElmer (MA, 
USA) and fluorescent signals were quantified using Regions of Interest (ROIs) and quantified 
as photons emitted using Living Image/Igor Pro Software (Caliper Life Sciences). 
 
In vivo efficacy and biodistribution of Cy5-labelled pHPMA-DOX conjugates 
In vivo experiments in MB-MDA-231 fLuc breast cancer tumor bearing mice were 
performed in order to assess efficacy, distribution and organ accumulation Cy5-labelled 
pHPMAs of different architectures. The experiments were conducted under the UK Home 
Office Licence number PPL P435A9CF8. LASA good practice guidelines, FELASA working 
group on pain and distress guidelines and ARRIVE reporting guidelines were also followed.  
50 6-7 week old female immunodeficient CD-1 NuNu mice were purchased from Charles 
River UK. Mice were maintained in Individually Ventilated Cages (Tecniplast UK) within a 
barriered unit, illuminated by fluorescent lights set to give a 12 hour light-dark cycle (on 07.00, 
off 19.00), as recommended in the guidelines to the Home Office Animals (Scientific 
Procedures) Act 1986 (UK). The room was air-conditioned by a system designed to maintain 
an air temperature range of 21 ± 2 ºC and a humidity of 55% ± 10%. Mice were housed in 
social groups, 3 per cage, during the study, with irradiated bedding and autoclaved nesting 
materials and environmental enrichment (Datesand UK). Sterile irradiated 5V5R rodent diet 
(IPS Ltd, UK) and autoclaved water was offered ad libitum. The condition of the animals was 
monitored throughout the study by an experienced animal technician. After a week’s 
acclimatization, the mice were initiated with tumors as follows.  
The cells were maintained in vitro in RPMI culture medium (Sigma, UK) containing 10% 
(v/v) heat inactivated fetal bovine serum (Sigma, Poole, UK) & 2 mM L-glutamine (Sigma, 
UK) at 370C in 5% CO2 and humidified conditions. Cells from sub-confluent monolayers were 
harvested with 0.025% EDTA, washed in culture medium and counted.  Cells with viability of 
>90% were re-suspended and seeded at 2x106 cells  per T150 flask and incubated for 48 hours. 
On day of initiation cells were harvested from semi-confluent monolayers with 0.025% EDTA, 
washed twice in the culture medium and counted 3 times as above. Cells with viability of >90% 
were re-suspended for in vivo administration in standard or growth factor reduced matrigel at 
2x106/ml for injection of 100 µl into the left mammary fat pad just inferior to the nipple. Tumor 
establishment and growth was monitored during the experiment by 2D optical imaging, carried 
out under anesthesia in an IVIS Spectrum detailed later weekly, and were also measured by 
Vernier calipers (Camlab) twice weekly and animals weighed weekly. The tumor volumes were 
calculated using a standard volume formula as previously reported (tumor volume = ½ 
(length × width 2). Dosing commenced on day 17 when the tumors had reached a suitable size 
as established by caliper measurement and bioluminescent imaging, average diameters around 
6 mm. Animals were randomized by volume and bioluminescence intensity, with group 
numbers of 10 mice per group. Injections were delivered on days 1, 3, 5, 8, 10, 12 or days 1, 3, 
7, 11, 18 by the intravenous route. After warming the mice in a thermostatically controlled 
heating box (Datesand UK), they were injected intravenously via the tail vein with 100ul of a 
500uM solution of the selected polymer type in PBS. No adverse effects were observed 
following the injections or for the duration of the study. The concentration delivered was 
determined from a balance of non-toxicity from in vitro analysis as well as sufficient 
fluorescent intensity for imaging in vivo. Imaging was carried out weekly as follows: the mice 
were anaesthetized with an injectable anesthetic combination (Anaestemine 
[ketamine]/Sedastart [medetomadine], Animalcare Ltd. UK) before being placed in the 
imaging system. At the pre-determined scientific end point (28-29 days) animals were culled 
by cervical dislocation, tissues were dissected out and were imaged ex vivo. The tissues excised 
and imaged were the tumor, kidneys, liver, spleen, pancreas, lung, heart, bladder, brain and 
lymph nodes (subiliac). A urine sample (25 µl) was also collected and imaged. In addition, the 
tumor, spleen and heart were weighed prior to preservation. All organs were preserved by snap 
freezing and fixation (NBF) 50:50. All images were collected using the IVIS® Spectrum 
imaging system, PerkinElmer (MA, USA) and fluorescent signals were quantified using 
Regions of Interest (ROIs) and quantified as photons emitted using Living Image/Igor Pro 




Figure S1. Representative 1H NMR of top: redox-responsive hyperbranched polymer (HB-SS-
HH) and bottom: non-degradable hyperbranched HPMA (HB-HPMA-S). The diagnostic 
resonances for molecular weight characterization have been highlighted. 
 
Figure S2. 1H NMR spectra of top) Star-SS-L, middle) Linear-SS and bottom) Micelle-SS. 
The resonances of the boc-protected hydrazide monomer have been highlighted. Note: the 
NMR visibility of the proton signals is disappeared for the micelle due to the self-assembly.  
 




Figure S4. Stability of non-degradable and redox-responsive pHPMAs in cell culture DMEM 
over 48 h incubation at 37 ºC.
 
Figure S5. Stability of pHPMAs to protein corona binding assayed by DLS at A) 0.2 wt% 
BSA and B) 1 wt% BSA.  
 
Figure S6. In vitro cell viability for all pHPMA materials in triple negative breast cancer 
cells. 
 
Figure S7. In vitro data depicting A) metabolic activity and B) LDH release of pHPMAs 
after 24h incubation with RAW 264.7 macrophages 
 
Figure S8. Macrophage uptake data showing A) influence of size on uptake (4h), B) 
influence of zeta-potential on uptake (4h), C) zeta-potential vs size of nanoparticles and D) 
ratio of zeta-potential / size vs uptake.  
 
Figure S9. Fluorescence microscopy confirming intracellular localization of pHPMAs during 
macrophage uptake studies (scale bar: 25 µm).   
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Figure S10. Quantitation of the fluorescence signal in the heart at all times, indicative of 
circulating nanoparticles (n = 2 ± SD). 
 
Figure S11. 1H NMR spectra of a representative pHPMA before and after Boc-deprotection. 
 
Figure S12. Assigned 1H NMR spectra of HB-SS-HH-DOX following purification by 
precipitation and dialysis.  
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Figure S13. UV-Vis calibration curve of DOX in PBS.   
 
 
Figure S14. Stability of polymer prodrugs in 0.2wt% BSA and DMEM cell culture medium. 
 
Figure S15. Fluorescence microscopy images of HB-SS-HH-DOX into MDA-MB-231 cells 
after 1h, 2h and 4h of incubation at 10x optical zoom.  
 
Figure S16. Fluorescence microscopy images of HB-SS-HH-DOX into MDA-MB-231 cells 
after 2h of incubation at 20x optical zoom.  
 
Figure S17. Spheroid cytotoxicity assay of the blank Cy5 labelled polymers to confirm no 
impact on spheroid growth from the blank nanoparticles. A) spheroid growth over 72h 
treatment, B) cytotoxicity of Cy5 polymers in 2D and 3D culture, C) growth of spheroids 
expressed as volume each day, D) volume comparison between day 4 and day 7 and E) % 
change in volume over the treatment period.  
 
Figure S18. Growth of MDA-MB-231 spheroids over the 3-day treatment period expressed 
as top) volume on each day and bottom) volume comparison between day 4 and 7.  
 
Figure S19. Fluorescence images of Cy5-labelled nanoparticles captured 24h after injection 
into MDA-MB-231 tumor-bearing mice. It can be seen for both nanoparticles that there is 
Cy5 signal from within the region of the tumor, as well as within the kidneys as observed in 









Figure S20. Luminescence images of MDA-MB-231 tumor-bearing mice at day 17 (pre-












Figure S22. 1H NMR spectra of EDMA
 
Figure S23. 1H NMR spectra of tBHM 
 
 
Figure S24. 1H NMR spectra of CBMA 
 
Figure S25. 1H NMR of CADB-SS-CADB
 
Figure S26. 13C NMR spectra of CADB-SS-CADB 
 
